A Subsidiary of Univercells Group
Univercells Technologies was launched in May 2020 as a subsidiary of Univercells focusing on the development and commercialization of the technology portfolio initially developed by Univercells, including the scale-X™ single-use bioreactor and the NevoLine™ biomanufacturing platform.
Experienced entrepreneurs Hugues Bultot and José Castillo established Univercells in 2013. They seek the development of technologies in order to have a direct and meaningful impact on the way biologics are manufactured worldwide.
$12M grant to develop a vaccine platform
Bill and Melinda Gates Foundation granted Univercells $12M to develop a biomanufacturing platform to deliver inactivated polio (sIPV) vaccine doses at affordable costs and with a reduced footprint. This development is the first application and proof of concept of the NevoLine™ biomanufacturing platform.
New Equipment Design Center
Univercells inaugurated the new Equipment Design & Production Center in Nivelles, Belgium. Today the facility fosters Univercells Technologies’ activities including the development and delivery of state-of-art high-performance, scalable bioproduction technologies for viral products.
Introducing the NevoLine™ sIPV platform
Two years after receiving the Bill & Melinda Gates Foundation grant of $12M, Univercells introduced the NevoLine platform proof of concept to deliver affordable inactivated polio vaccine (sIPV). This first application demonstrated how the chaining of unit operations could intensify processes for drastic footprint and cost reductions.
€50M to speed delivery of manufacturing technologies
Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, supports Univercells Technologies activities by financing $50M. The investment will be deployed on accelerating the industrialization and commercialization of the NevoLine™ biomanufacturing platform and the scale-X™ bioreactor portfolio.
Official launch of Univercells Technologies
With its own identity, Univercells Technologies will focus on the commercialization of the product portfolio – the scale-X™ bioreactor range and the NevoLine™ biomanufacturing platform. The company will also explore new technologies and solutions developments to deliver the next evolution of biomanufacturing.
Partnership with Exyte to create modular biomanufacturing facilities
In the wake of the COVID-19 pandemic, we partnered with Exyte to design a modular and flexible GMP manufacturing facilities for vaccines. Through this partnership, an integrated plant design combines Exyte’s prefabricated modular construction system, ExyCell, with the NevoLine biomanufacturing platform featuring the scale-X fixed-bed bioreactor at its core.
Introduction of the NevoLine™ Upstream platform
The new generation NevoLine platform builds upon the successfull proof of concept for sIPV manufacture designed and developped by Univercells. The NevoLine Upstream platform redefines upstream processing by integrating virus production, concentration and clarification for streamlined, high-performance virus manufacturing in a 3 m² footprint equipment.